Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease.
A new oral vaccine for Alzheimer's disease was developed using recombinant adeno-associated virus vector carrying Abeta cDNA (AAV/Abeta). Oral administration of the vaccine without adjuvant induced the expression and secretion of Abeta1-43 or Abeta1-21 in the epithelial cell layer of the intestine in amyloid precursor protein transgenic mice. Serum antibody levels were elevated for more than six months, while T cell proliferative responses to Abeta was not detected. Brain Abeta burden was significantly decreased compared to the control without inflammatory changes. This oral AAV/Abeta vaccine seems to be promising for prevention and treatment of Alzheimer's disease.
Hara
Hideo
H
National Institute for Longevity Sciences, NCGG, 36-3 Gengo, Morioka, Obu City, Aichi 474-8522, Japan. hhara@nils.go.jp
Monsonego
Alon
A
Yuasa
Katsutoshi
K
Adachi
Kayo
K
Xiao
Xiao
X
Takeda
Shin'ichi
S
Takahashi
Keikichi
K
Weiner
Howard L
HL
Tabira
Takeshi
T
D000284:Administration, Oral; D000544:Alzheimer Disease / Q000276:immunology / Q000517:prevention & control*; D023582:Alzheimer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D016229:Amyloid beta-Peptides / Q000276:immunology / Q000378:metabolism; D000818:Animals; D015703:Antigens, CD / Q000276:immunology; D015153:Blotting, Western; D017931:DNA Primers / Q000235:genetics; D018076:DNA, Complementary / Q000378:metabolism; D000229:Dependovirus / Q000235:genetics*; D004797:Enzyme-Linked Immunosorbent Assay; D005822:Genetic Vectors / Q000235:genetics*; D007150:Immunohistochemistry; D051379:Mice; D008822:Mice, Transgenic
D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D015703:Antigens, CD; D017931:DNA Primers; D018076:DNA, Complementary